The 10-second takeaway
For the quarter ended March 31 (Q2), Avanir Pharmaceuticals beat slightly on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly. GAAP loss per share dropped.
Gross margins dropped, operating margins increased, net margins grew.
Avanir Pharmaceuticals chalked up revenue of $17.4 million. The six analysts polled by S&P Capital IQ predicted revenue of $17.2 million on the same basis. GAAP reported sales were 74% higher than the prior-year quarter's $10.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.12. The five earnings estimates compiled by S&P Capital IQ forecast -$0.09 per share. GAAP EPS were -$0.12 for Q2 against -$0.13 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 94.2%, 50 basis points worse than the prior-year quarter. Operating margin was -88.8%, much better than the prior-year quarter. Net margin was -94.8%, much better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $19.4 million. On the bottom line, the average EPS estimate is -$0.07.
Next year's average estimate for revenue is $83.5 million. The average EPS estimate is -$0.23.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 182 members out of 243 rating the stock outperform, and 61 members rating it underperform. Among 49 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 37 give Avanir Pharmaceuticals a green thumbs-up, and 12 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Avanir Pharmaceuticals is outperform, with an average price target of $5.60.
- Add Avanir Pharmaceuticals to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.